AxoFuse® consists of four (4) sterile solutions and a device for focal, topical application (directly to the affected nerve) that,
when applied sequentially according to the instructions for use, comprise a therapeutic addition to standard surgical repair (microsuturing) for patients
with acute peripheral nerve injuries. The process is referred to as PEG-fusion. The delivery device component of the AxoFuse® kit serves to concentrate drug exposure
at the injury site and protect the surrounding tissues from exposure.
Extensive testing in animals with peripheral nerve injuries has demonstrated that PEG-fusion results in dramatically faster and more improved outcomes compared with animals treated with the contemporary standard of care in clinical practice. Use of the AxoFuse® delivery device with PEG-fusion has demonstrated similarly rapid and improved injury recovery as PEG-fusion alone with the added benefit of tissue protection.
AxoFuse® is being developed for use within 2-3 days of traumatic injuries resulting in peripheral nerve damage. The product is not currently available for sale or for use in clinical practice.